Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Uterine Cervical Neoplasms 2 Polycystic Ovary Syndrome 2 Vaginal Atrophy 1 Triple Negative Breast Neoplasms 1 Sexual Dysfunction, Physiological 1 Sarcoma, Synovial 1 Rectal Neoplasms 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Metastatic Breastcancer 1 Insulin Resistance 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Endocrine System Diseases 1 Depression 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1 Anxiety Disorders 1 Anus Neoplasms 1

Interventions

Cyclophosphamide 10 fludarabine 5 Radiotherapy 5 Doxorubicin 5 Gemcitabine 3 sargramostim 2 fludarabine phosphate 2 aldesleukin 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Nivolumab 2 Leukapheresis 2 Ifosfamide 2 Docetaxel 2 Decitabine 2 Dacarbazine 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 trofosfamide 1 tremelimumab 1 temsirolimus 1 sotigalimab 1 ribociclib 1 poly ICLC 1 pembrolizumab 1 pegfilgrastim 1 pazopanib 1 pasireotide 1 olaparib 1 lutetium Lu 177 dotatate 1 liposomal doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma, Synovial × Dehydroepiandrosterone × Clear all

NCT02683148 2019-09-09

DHEA in Synovial Sarcoma Patients

Washington University School of Medicine

Phase 1 Terminated

Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡